Psilocybin for Alcohol Use Disorder: Drinking, Relapse and Recovery

Andrew T. Austin · 11 October 2026

Alcohol use disorder is a clinical condition requiring sustained care. Describing it as a failure of willpower obscures the needs that treatment must address. Drinking can become organised around relief from withdrawal, anxiety, shame or loneliness, even as it damages the relationships and capacities on which recovery depends. Psilocybin-assisted therapy is of interest because it may help some people reconsider these entrenched patterns. The clinically important question is whether that change persists when ordinary pressures return.

There is credible evidence that psilocybin combined with structured psychological treatment can reduce heavy drinking in some adults. There is also a controlled trial in which it did not significantly improve the principal drinking outcomes after detoxification. It remains a promising, developing approach whose value depends on the patient population, the treatment surrounding the drug and the outcome being sought.¹²

On this page

• What needs to change in alcohol use disorder?
• How psilocybin might support behavioural change
• Evidence for reducing heavy drinking
• Why relapse prevention after detoxification is a separate question
• Psychological care before and after the session
• Psilocybin does not treat dangerous alcohol withdrawal
• Safety, coexisting illness and medication
• How it compares with established treatment
• Assessing sustained recovery

What needs to change in alcohol use disorder?

Alcohol use disorder involves impaired control over drinking and continuing alcohol use despite significant consequences. Physical dependence may be present, but it does not describe the whole condition. Assessment must also address mood, other substance use, medical illness, cognitive difficulties, social circumstances and the person’s priorities. The appropriate goal may be abstinence or a reduction in harmful drinking, although substantial dependence and medical complications often make abstinence the safer objective.³

Recovery cannot be judged solely by whether an individual reports less desire to drink immediately after an emotionally powerful session. Craving is important, but a person may feel little craving in a protected environment and encounter severe difficulty after returning to a household, workplace or social network organised around alcohol. Conversely, someone may continue to experience cravings while developing an increasingly effective capacity to respond without drinking.

That distinction matters when discussing rapid treatments. A change in perspective can be valuable without removing the need for practical help. Secure housing, treatment of coexisting depression, a workable response to drinking cues and access to continuing support may determine whether an initial improvement can be sustained. These factors belong within treatment planning and the assessment of outcomes.

How psilocybin might support behavioural change

Psilocybin is converted to psilocin, which acts at serotonin receptors, particularly the 5-HT_2A receptor associated with its characteristic psychedelic effects. At the doses investigated in assisted therapy, it can profoundly alter perception, emotion and the experience of oneself. Proposed therapeutic mechanisms include changes in psychological flexibility, emotional learning and the accessibility of previously avoided material. These remain explanations under investigation, rather than a complete account of how recovery occurs.⁴⁵

A possible opportunity for behavioural change is a more precise description than a brain “reset”, which suggests a predictable repair that neuroscience has not established. A person may become more aware of the costs of drinking, experience renewed connection with others or consider a different future. None of those experiences automatically produces the skills, social resources or medical stability needed to maintain that future.

The subjective force of an experience also does not guarantee that every conclusion drawn during it is accurate. Intense certainty can accompany mistaken interpretations as well as useful insight. Support after a session should allow ideas to be examined, revised and translated into manageable actions, rather than treating the experience as an unquestionable revelation.⁶

Evidence for reducing heavy drinking

In a 2022 randomised trial, 95 adults were assigned to psilocybin or the active comparator diphenhydramine, alongside a 12-week psychotherapy programme; 93 received medication and entered the primary analysis. Treatment involved two medication sessions. Across the following 32 weeks, heavy-drinking days averaged 9.7% with psilocybin and 23.6% with the comparator. The difference was 13.9 percentage points, with a 95% confidence interval of 3.0 to 24.7.¹

This is a clinically encouraging result. It is not equivalent to saying that most participants became continuously abstinent. It also concerns a combined treatment: psychological care was provided in both groups. The comparison did not establish superiority to naltrexone, acamprosate or another complete addiction-treatment programme. Recognisable psychedelic effects made concealment of treatment allocation difficult, which limits certainty about the contribution of expectation.¹

These findings support further clinical development, with a meaningful signal on heavy drinking. A group average cannot predict an individual patient’s response. The confidence interval itself shows that the precise size of benefit remains uncertain.

Why relapse prevention after detoxification is a separate question

Maintaining abstinence after withdrawal treatment places different demands on a therapy from reducing heavy drinking in people recruited from the community. A Swiss randomised trial published in 2025 investigated a single psilocybin session with five psychotherapy sessions after alcohol withdrawal treatment. Among 37 participants completing the four-week assessment, there was no significant difference between groups in abstinence duration or average alcohol consumption. Six-month drinking outcomes also failed to show a significant benefit.²

Some craving measures improved more with psilocybin, but that did not translate into a demonstrated advantage on the primary drinking outcomes. The small sample limits precision: it cannot establish that every form of psilocybin-assisted care is ineffective. Equally, it cannot be dismissed merely because its result is less favourable. It tests the assumption that a comparatively brief intervention can reliably prevent relapse in this setting, and does not support that assumption.²

A separate French feasibility trial enrolled 30 people with severe alcohol use disorder and depressive symptoms after detoxification. Two psilocybin sessions were added to intensive standard care. Some secondary drinking measures favoured the higher-dose condition, but the principal purpose was to assess feasibility. The small groups, imperfect blinding and selective positive outcomes make these preliminary findings, rather than a definitive demonstration of effectiveness for people with both conditions.⁷

Psychological care before and after the session

The intervention requires more than a comfortable room and reassurance on the medication day. Preparation should establish realistic expectations, identify the person’s drinking pattern and explain the possibility of anxiety, confusion or emotional distress. Consent must include the right to decline participation without losing access to ordinary addiction care. Staff need clear boundaries and the competence to recognise psychiatric and medical problems.⁸

Afterwards, psychological support can help the person connect any useful insight with specific situations: an argument at home, the end of a working day, a familiar route past an off-licence or the experience of being alone. An intention to improve self-care becomes more useful when it is linked to an achievable plan, sources of support and a response to predictable difficulties. This is a practical therapeutic judgement; a moving account of a session cannot substitute for evidence that daily life has improved.

Family involvement can be helpful when wanted and safe, but it should not become surveillance or coercion. Some relationships are supportive; others contribute to distress or expose a person to harm. Psychological and social interventions therefore need to be selected around the individual, rather than added as a uniform accompaniment to the drug.³

Psilocybin does not treat dangerous alcohol withdrawal

Alcohol withdrawal can cause seizures and delirium tremens. Psilocybin is not an established treatment for either complication and should not be presented as a means of making abrupt withdrawal safe. People who are physically dependent may need medically assisted withdrawal, with the setting and treatment determined by the severity of dependence, previous complications and current health.⁹

The distinction between withdrawal treatment and longer-term relapse prevention is fundamental. A treatment discussed as a possible aid to longer-term behavioural change can become dangerous if its reputation encourages someone to bypass the immediate medical needs of dependence. The post-detoxification trials began after withdrawal treatment; they do not provide evidence for managing withdrawal itself.²⁷

Safety, coexisting illness and medication

Acute psilocybin effects can include anxiety, nausea, headache and increases in blood pressure. The absence of frequent serious events in a small, screened sample does not establish safety for every person attending an addiction service. Psychiatric history, cardiovascular health and the person’s ability to engage with preparation and follow-up remain relevant. Trials commonly exclude some of the people whose clinical circumstances are most complex.¹⁰¹¹

Medication review is particularly important where alcohol dependence coexists with depression, pain or another substance use disorder. Interactions may alter the psychedelic response, create additional risks or complicate interpretation of new symptoms. The evidence for many combinations is incomplete. Online discussion of whether a particular drug “blocks” a psychedelic effect cannot establish that a medication change is safe.¹²

Discontinuing an effective treatment can itself cause harm. A clinically responsible discussion must consider the consequences of changing medication as well as the possible consequences of combining it with psilocybin. Failure to have an intense experience is not, by itself, a reason to escalate treatment or withdraw other care.

How it compares with established treatment

Existing treatments deserve an accurate account. NICE recommends psychological interventions and, for suitable people after successful withdrawal from moderate or severe dependence, consideration of acamprosate or oral naltrexone alongside psychological treatment. Selection requires medical assessment and attention to contraindications. These are available clinical options, rather than a control condition that can be assumed to offer little benefit.³

Psilocybin-assisted treatment has not yet answered several practical comparative questions: whether it produces better outcomes than well-delivered established care, whether any additional benefit justifies the staffing involved, and how outcomes vary with repeated treatment or longer follow-up. Access to suitable alternatives also matters for people unable to attend lengthy sessions. An intervention’s effectiveness in practice includes its accessibility and continuity.

A return to drinking should prompt reassessment, not a judgement that the patient failed to surrender, integrate or think positively enough. It may reveal an untreated illness, a mismatch between goals and circumstances, or the need for more intensive support. The language of transformation should never make continuing care conditional on an impressive personal story.

Assessing sustained recovery

Benefit should be assessed over time across drinking patterns, medical complications, mood, functioning, relationships and the person’s own priorities. A short-lived improvement may still matter, but it should be named accurately. Recovery that lasts through stressful periods has a different significance from a favourable questionnaire completed shortly after a session.

Psilocybin-assisted therapy warrants further investigation for alcohol use disorder, including for people whose needs are not adequately met by present services. Its promise is strongest when described precisely: a possible addition to comprehensive addiction care, with encouraging findings in some settings and important negative findings in others. The standard should be sustained benefit with acceptable harm, rather than the intensity of the experience.

References

1. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79:953–962. doi:10.1001/jamapsychiatry.2022.2096.
2. Rieser NM, Bitar R, Halm S, et al. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine. 2025;82:103149. doi:10.1016/j.eclinm.2025.103149.
3. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115). Recommendations; accessed 11 October 2026.
4. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355. doi:10.1124/pr.115.011478.
5. de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry. 2021;12:724606. doi:10.3389/fpsyt.2021.724606.
6. McGovern HT, Grimmer HJ, Doss MK, et al. An Integrated theory of false insights and beliefs under psychedelics. Commun Psychol. 2024;2:69. doi:10.1038/s44271-024-00120-6.
7. Luquiens A, Belahda D, Graux C, et al. Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. Published online 24 July 2025. doi:10.1111/add.70152.
8. Johnson MW, Richards WA, Griffiths RR. Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol. 2008;22:603–620. doi:10.1177/0269881108093587.
9. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis and management of physical complications (CG100). Recommendations; accessed 11 October 2026.
10. Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7:e245960. doi:10.1001/jamanetworkopen.2024.5960.
11. Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81:1225–1235. doi:10.1001/jamapsychiatry.2024.2546.
12. Halman A, et al. Drug–drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024. doi:10.1177/02698811231211219.

General medical information. Decisions about treatment, medication changes and persistent symptoms require an individual assessment by an appropriately qualified clinician.